Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer

Next Previous
X
Search
Trial Profile

A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorine-18 PSMA 1007 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Sponsors Centre for Probe Development and Commercialization

    • Most Recent Events

    • 05 Feb 2024 Status changed from recruiting to completed.
    • 28 Jun 2022 According to a Centre for Probe Development and Commercialization media releases, it executes its first commercial sublicensing agreement with Lawson Health Research Institute for PSMA-1007, expanding access to the prostate cancer diagnostic agent in Ontario
    • 24 Feb 2021 According to the Centre for Probe Development and Commercialization (CPDC) Media release, the first patient has been dosed and imaged in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top